Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...

A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

Indian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...

Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...

A new study reveals that generic drugs made in India are linked to a significantly higher number of severe adverse events, ...

New Delhi, A trends study conducted by the federal financial intelligence unit of India has expressed "suspicion" that ...